共 151 条
[1]
Gudlaugsson O.(2003)Attributable mortality of nosocomial candidemia, revisited Clin. Infect. Dis. 37 1172-1177
[2]
Gillespie S.(2006)Current treatment strategies for disseminated candidiasis Clin. Infect. Dis. 42 244-251
[3]
Lee K.(2002)Overview of the lipid formulations of amphotericin B J. Antimicrob. Chemother. 49 31-36
[4]
Vande Berg J.(1999)Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia N. Engl. J. Med. 340 764-771
[5]
Hu J.(2004)Combination antifungal therapy Antimicrob. Agents Chemother. 48 693-715
[6]
Messer S.(2005)Combination treatment of invasive fungal infections Clin. Microbiol. Rev. 18 163-194
[7]
Herwaldt L.(1985)Combined effect of antifungal agents—Fundamental study on amphotericin B and flucytosine Jpn. J. Med. Mycol. 26 126-132
[8]
Pfaller M.(2004)Combination therapy for invasive mycoses: Evaluation of past clinical trial designs Clin. Infect. Dis. 39 S224-S227
[9]
Diekema D.(1977)Therapy of murine aspergillosis with amphotericin B in combination with rifampin of 5-fluorocytosine Antimicrob. Agents Chemother. 11 21-25
[10]
Spellberg B.(2002) interaction of flucytosine combined with amphotericin B or fluconazole against thirty-five yeast isolates determined by both the fractional inhibitory concentration index and the response surface approach Antimicrob. Agents Chemother. 46 2982-2989